Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PN 10943A (Primary)
  • Indications Inflammatory bowel diseases; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 06 Nov 2019 According to a Protagonist Therapeutics media release, results were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
    • 01 Aug 2019 According to a Protagonist Therapeutics media release, complete data from the trial will be presented at the American College of Gastroenterology Conference in October 2019.
    • 01 Aug 2019 Results presented in the Protagonist Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top